CSL Overview
- Year Founded
-
1916
- Status
-
Public
- Employees
-
22,000
- Stock Symbol
-
CSL
- Investments
-
10
- Share Price
-
$158.06
- (As of Tuesday Closing)
CSL General Information
Description
CSL is one of the largest global biotech companies and has two main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders and neurological indications. Seqirus is now the world's second largest influenza vaccination business and was acquired in fiscal 2015. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
Contact Information
Website
www.csl.comCorporate Office
- 655 Elizabeth Street
- Melbourne, Victoria 3000
- Australia
Corporate Office
- 655 Elizabeth Street
- Melbourne, Victoria 3000
- Australia
CSL Timeline
CSL Stock Performance
As of 18-Mar-2025, CSL’s stock price is $158.06. Its current market cap is $76.5B with 484M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $158.06 | $156.80 | $155.16 - $210.58 | $76.5B | 484M | 779K | $5.47 |
CSL Financials Summary
As of 30-Jun-2024, CSL has a trailing 12-month revenue of $14.7B.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2024 30-Jun-2024 | FY 2023 30-Jun-2023 | FY 2022 30-Jun-2022 |
|---|---|---|---|---|
| EV | 107,948,969 | 107,948,969 | 101,285,180 | 88,379,872 |
| Revenue | 14,690,000 | 14,690,000 | 13,174,000 | 10,493,100 |
| EBITDA | 4,750,000 | 4,750,000 | 3,900,000 | 3,482,700 |
| Net Income | 2,642,000 | 2,642,000 | 2,194,000 | 2,254,700 |
| Total Assets | 38,022,000 | 38,022,000 | 36,234,000 | 28,346,000 |
| Total Debt | 12,183,000 | 12,183,000 | 12,227,000 | 9,657,800 |
CSL Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
CSL Comparisons
Industry
Financing
Details
CSL Competitors (22)
One of CSL’s 22 competitors is Novavax, a Corporation company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Novavax | Corporation | Gaithersburg, MD | ||||
| Taibang Biological Group | Private Equity-Backed | Beijing, China | ||||
| EMD Serono | Corporation | Boston, MA | ||||
| Takeda Pharmaceutical | Corporation | Tokyo, Japan | ||||
| Teva Pharmaceutical Industries | Corporation | Tel Aviv, Israel |
CSL Patents
CSL Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024901842-A0 | Anti-c2 antibodies and uses thereof | Pending | 17-Jun-2024 | ||
| AU-2024901841-A0 | Multifunctional fcrn antagonists and uses thereof | Pending | 17-Jun-2024 | ||
| AU-2024901051-A0 | Protein formulations and uses thereof | Pending | 15-Apr-2024 | ||
| AU-2024900957-A0 | Protein formulations and uses thereof | Inactive | 05-Apr-2024 | ||
| AU-2024900302-A0 | Methods of delaying progression or hindering development of surgery-associated systemic inflammation | Pending | 09-Feb-2024 |
CSL Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
CSL Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
CSL Investments & Acquisitions (10)
CSL’s most recent deal was a Merger/Acquisition with CSL Vifor for . The deal was made on 09-Aug-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CSL Vifor | 09-Aug-2022 | Merger/Acquisition | Pharmaceuticals | ||
| Ena Respiratory | 15-Jun-2021 | Later Stage VC | Drug Discovery | ||
| Denteric | 26-Sep-2019 | Early Stage VC | Drug Discovery | ||
| Zhongyuan Ruide | 21-Jun-2018 | Secondary Transaction - Private | Drug Discovery | ||
| Calimmune | 28-Aug-2017 | Merger/Acquisition | Biotechnology |
CSL ESG
Risk Overview
Risk Rating
Updated March, 05, 2025
26.21 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,946
Rank
Percentile
Pharmaceuticals
Industry
of 847
Rank
Percentile
Biotechnology
Subindustry
of 366
Rank
Percentile
CSL Exits (3)
CSL’s most recent exit was on 21-Jun-2018 from Zhongyuan Ruide. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Zhongyuan Ruide | 21-Jun-2018 | Completed |
|
||
| Zhongyuan Ruide | 03-Aug-2017 | Completed |
|
||
| Environmental Support Solutions | 09-Apr-2006 | Later Stage VC | Completed |
|
CSL Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| CSL Plasma | 2019 | ||
| CSL Vifor | Glattbrugg, Switzerland | 1927 | |
| Seqirus | Holly Springs, NC | 1916 |
CSL FAQs
-
When was CSL founded?
CSL was founded in 1916.
-
Where is CSL headquartered?
CSL is headquartered in Melbourne, Australia.
-
What is the size of CSL?
CSL has 22,000 total employees.
-
What industry is CSL in?
CSL’s primary industry is Biotechnology.
-
Is CSL a private or public company?
CSL is a Public company.
-
What is CSL’s stock symbol?
The ticker symbol for CSL is CSL.
-
What is the current stock price of CSL?
As of 18-Mar-2025 the stock price of CSL is $158.06.
-
What is the current market cap of CSL?
The current market capitalization of CSL is $76.5B.
-
What is CSL’s current revenue?
The trailing twelve month revenue for CSL is $14.7B.
-
Who are CSL’s competitors?
Novavax, Taibang Biological Group, EMD Serono, Takeda Pharmaceutical, and Teva Pharmaceutical Industries are some of the 22 competitors of CSL.
-
What is CSL’s annual earnings per share (EPS)?
CSL’s EPS for 12 months was $5.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
